General Partner

Actavis plc (NYSE: ACT) completed on March 17, 2015 the acquisition of Allergan, creating a diversified global pharmaceutical company. The combined company is focused on developing new medicines that address unmet medical needs in critical therapeutic areas, as well as increasing global access to high-quality, affordable medicines.

The Actavis + Allergan Brand portfolio features six franchises in key therapeutic categories, including Dermatology and Aesthetics; CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular and Infectious Disease.

Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.

The Actavis + Allergan Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The combined company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets.

www.actavis.com

News

Live Online Broadcasting

Watch live online according to the conference programme on 5th and 6th June 2015

5th CME CVS

Athens, June 5-6, 2015

4th CME CVS 2014

Summary, lectures, archive

Live Broadcasting